{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(6)"],"submitter":["Holzhauser S"],"pubmed_abstract":["Human papillomavirus positive (HPV<sup>+</sup>) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have better outcomes than corresponding HPV<sup>-</sup> negative (HPV<sup>-</sup>) cancer cases. Our previous study demonstrated that fibroblast growth factor receptor 3 (FGFR3) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) are often mutated in HPV<sup>+</sup> cancer. To investigate whether targeted therapy is an option for TSCC/BOTSCC, two HPV<sup>+</sup> and one HPV<sup>-</sup> TSCC/BOTSCC cell lines were tested for their sensitivity towards FGFR and PI3K inhibitors. The HPV<sup>+</sup> cell lines UM-SCC-47 and UPCI-SCC-154, and the HPV<sup>-</sup> cell line UT-SSC-60A were tested by competitive allele-specific TaqMan-PCR for presence/absenc"],"journal":["Oncology letters"],"pagination":["6249-6260"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6865836"],"repository":["biostudies-literature"],"pubmed_title":["<i>In vitro</i> antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines."],"pmcid":["PMC6865836"],"pubmed_authors":["Kostopoulou ON","Bersani C","Ohmayer A","Wickstrom M","Ramqvist T","Holzhauser S","Andonova T","Dalianis T","Lange BKA"],"additional_accession":[]},"is_claimable":false,"name":"<i>In vitro</i> antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.","description":"Human papillomavirus positive (HPV<sup>+</sup>) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have better outcomes than corresponding HPV<sup>-</sup> negative (HPV<sup>-</sup>) cancer cases. Our previous study demonstrated that fibroblast growth factor receptor 3 (FGFR3) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) are often mutated in HPV<sup>+</sup> cancer. To investigate whether targeted therapy is an option for TSCC/BOTSCC, two HPV<sup>+</sup> and one HPV<sup>-</sup> TSCC/BOTSCC cell lines were tested for their sensitivity towards FGFR and PI3K inhibitors. The HPV<sup>+</sup> cell lines UM-SCC-47 and UPCI-SCC-154, and the HPV<sup>-</sup> cell line UT-SSC-60A were tested by competitive allele-specific TaqMan-PCR for presence/absenc","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2025-04-22T00:27:56.386Z","creation":"2025-04-05T19:33:35.145Z"},"accession":"S-EPMC6865836","cross_references":{"pubmed":["31788102"],"doi":["10.3892/ol.2019.10973"]}}